Norovirus is a worldwide public health problem responsible for close to 90% of epidemic, non-bacterial outbreaks of gastroenteritis around the world. 

Norovirus is a very common and highly contagious virus that causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea. Other symptoms include fatigue, fever and dehydration. Noroviruses are a major cause of gastrointestinal illness in closed and crowded environments, having become notorious for their common occurrence in hospitals, nursing homes, childcare facilities and cruise ships.

In the U.S. alone, noroviruses are the most common cause of acute gastroenteritis, and are estimated to cause 21 million illnesses each year and contribute to 70,000 hospitalizations and 800 deaths. Noroviruses are responsible for up to 1.1 million hospitalizations and 218,000 deaths annually in children in the developing world. 

There is currently no effective treatment or effective vaccine for norovirus, and the ability to curtail outbreaks is limited. Few companies, if any, are developing antiviral treatments for this disease. 

By targeting viral replication enzymes and protease, we believe it is possible to develop an effective treatment for all genogroups of norovirus. Also, because of the significant unmet medical need and the possibility of chronic norovirus infection in immunocompromised individuals, new antiviral therapeutic approaches may warrant an accelerated path to market.

We are developing inhibitors of the RNA-dependent RNA polymerase and protease of norovirus. These enzymes are essential to viral replication and are highly conserved between all noroviral genogroups. Therefore, an inhibitor of this enzyme might be an effective therapeutic treatment or short-term prophylactic agent when administered during a cruise or nursing home stay, for example. We have developed x-ray quality norovirus polymerase and protease crystals and have identified promising inhibitors. We are implementing the platform and approaches that have proven successful in our other antiviral programs.

To learn more about norovirus, please visit the information page at the Center for Disease Control and Prevention (CDC).


Noro Polymerase and Protease Inhibitors

Program Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3
Norovirus Gastroenteritis Replication and Protease Inhibitors
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started

We continue to identify and develop non-nucleoside polymerase inhibitors using our proprietary structure-based drug design technology platform. In 2020, we entered into a License Agreement with the Kansas State University Research Foundation to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat norovirus and coronavirus infections. Preclinical activities for our Norovirus program are currently under way.